Machado-Joseph Disease in Israel

Spinocerebellar Ataxia 3 Clinical Trial

Official title:
Machado-Joseph Disease in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation

Status Recruiting

Clinical Trial Summary

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA-3) is the most common dominant ataxia. The genetic cause of this late-onset degenerative disorder is the expansion of a (CAG)n tract located in the exonic region of the ATXN3 gene. In 1994 the first case of MJD among the Yemenite Jewish subpopulation living in Israel was published. The puropse of this study is to describe the clinical phenotype and genotype of the Yemenite Jewish subpopulation with MJD living in Israel

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02175290
Study type	Observational [Patient Registry]
Source	Meir Medical Center
Contact	Carlos R Gordon, MD;DSc
Phone	972-9-7471581
Email	cgordon@post.tau.ac.il
Status	Recruiting
Phase	N/A
Start date	June 2014
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04426149` - Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3	N/A
Completed	`NCT03120013` - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia	N/A
Active, not recruiting	`NCT03408080` - Open Pilot Trial of BHV-4157	Phase 3
Completed	`NCT04153110` - Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia	N/A
Active, not recruiting	`NCT03487367` - Clinical Trial Readiness for SCA1 and SCA3